MPLT Stock Forecast & Price Target

MapLight Therapeutics is attractive because its lead asset ML-007C-MA targets a large, underserved CNS market with a differentiated muscarinic mechanism that could address schizophrenia and Alzheimer's disease psychosis with better tolerability and dosing convenience than existing options. The company’s ZEPHYR Phase 2 showed a 4.5-point placebo-adjusted PANSS improvement at week 5 with a Cohen’s d of 0.37, a cognitive signal, and only 7.1% discontinuation from TEAEs, while the ongoing VISTA trial in Alzheimer's disease psychosis is a potentially larger opportunity with topline expected in 2H27. Financially, management reported about $501M of cash and financing support through 2028, while the market appears to underappreciate the upside from a cleaner safety profile, potential mechanistic validation, and additional optionality from ML-004.

MapLight Therapeutics is facing a weak fundamental setup because ML-007C-MA has not yet shown enough differentiation to justify displacing Cobenfy, with the 330/6 QD arm missing, the negative-symptom readout also missing, and adverse events still material at 74.7% versus 48.1% placebo. The need for an additional Phase 3 study, and possibly another to test QD dosing, means the company remains exposed to execution risk while a contested class already includes an approved competitor and other late-stage programs. The lowered view on peak sales to about $400mn in schizophrenia and $2bn in ADP by 2037E, along with reduced operating expense assumptions and a DCF-based value cut from $43 to $24, underscores the limited commercial visibility.